Search results for "P-gp"

showing 5 items of 5 documents

Humanization of the Blood-Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus - Lessons from Three Unsuccessful Approaches

2018

ATP-binding cassette (ABC) transporters are of major importance for the restricted access of toxins and drugs to the human body. At the body's barrier tissues like the blood-brain barrier, these transporters are highly represented. Especially, ABCB1 (P-glycoprotein) has been a priority target of pharmaceutical research, for instance, to aid chemotherapy of cancers, therapy resistant epilepsy, and lately even neurodegenerative diseases. To improve translational research, the humanization of mouse genes has become a popular tool although, like recently seen for Abcb1, not all approaches were successful. Here, we report the characterization of another unsuccessful commercially available ABCB1 …

0301 basic medicinehumanizationPET imaginglcsh:QR1-502Locus (genetics)ATP-binding cassette transporterComputational biologyBiologyBlood–brain barrierlcsh:Microbiology03 medical and health sciencesExon0302 clinical medicinemedicineCoding regionmouse modelsGenePromoterABCB1: ABCB13. Good healthOriginal Research Paper030104 developmental biologymedicine.anatomical_structureHumanized mouseP-gpABC transporter030217 neurology & neurosurgeryEuropean journal of microbiology and immunology
researchProduct

Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

2021

Adenosine-triphosphate-(ATP)-binding cassette (ABC) transport proteins are ubiquitously present membrane-bound efflux pumps that distribute endo- and xenobiotics across intra- and intercellular barriers. Discovered over 40 years ago, ABC transporters have been identified as key players in various human diseases, such as multidrug-resistant cancer and atherosclerosis, but also neurodegenerative diseases, such as Alzheimer���s disease (AD). Most prominent and well-studied are ABCB1, ABCC1, and ABCG2, not only due to their contribution to the multidrug resistance (MDR) phenotype in cancer, but also due to their contribution to AD. However, our understanding of other ABC transporters is limited…

ABCG2 (BCRP)Multitarget inhibitor (PANABC)Broad-spectrum modulatorPolypharmacologyActivationNeurosciences. Biological psychiatry. NeuropsychiatryAmyloid-beta (Aβ / Abeta)ABCA2ABCA5ArticleABCA7InductionABCB1 (P-gp)Pattern analysisDownregulationPET Tracer (PETABC)ABC transporterABCA1 (ABC1)Rational drug design and developmentAlzheimer’s diseaseRC321-571ABCC1 (MRP1)InhibitionFree neuropathology
researchProduct

Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process.

2004

8 pages, 2 figures, 2 tables.--PMID: 15124220 [PubMed]

In situAbsorption (pharmacology)Maleverapamilmedicine.medical_specialtymRNAPharmaceutical ScienceWestern blotIn Vitro TechniquesIntestinal absorptionPharmacokineticsWestern blotInternal medicinemedicineAnimalsAlbuterolATP Binding Cassette Transporter Subfamily B Member 1Rats WistarP-glycoproteinmedicine.diagnostic_testbiologyintestinal absorptionintestinal secretionMolecular biologyP-glycoprotein (P-gp) expressionRatsEndocrinologyIntestinal Absorptionsalbutamolreverse transcription-polymerase chain reaction (RT-PCR)Salbutamolbiology.proteinbioavailabilityPerfusionmedicine.drugJournal of pharmaceutical sciences
researchProduct

In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition.

2017

Recently, we have reported that glycol chitosan (GCS) was able to reverse the P- glycoprotein (P-gp) efflux pump. The objective of the present study was to evaluate the potential of two GCS-based dosage forms (aqueous solution or nanoparticle suspension) for oral administration of the P-gp substrate Rho-123. A further aim of the present study was to assess the effect of the glycol chitosan-4-thiobutylamidine thiomer (GCS-TBA) on P-gp activity considering that the corresponding thiomer of chitosan series is a well-known P-gp inhibitor. Pre-treatment of Caco-2 cell monolayer with a GCS solution or GCS-based nanoparticles increased the absorptive transport of Rho-123 across the monolayer of 1.…

endocrine systemATP Binding Cassette Transporter Subfamily BPolymers and Plastics02 engineering and technologyPharmacologyDosage formChitosan03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDrug Delivery SystemsOral administrationhealth services administrationpolycyclic compoundsMaterials ChemistryHumansGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailabilityChitosanChemistryThiomerOrganic ChemistryGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailability021001 nanoscience & nanotechnologyBioavailabilityCaco-2Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisNanoparticlessense organsEffluxCaco-2 Cells0210 nano-technologyhormones hormone substitutes and hormone antagonistsConjugateCarbohydrate polymers
researchProduct

Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia

2022

Drug resistance is the ability of cancer cells to gain resistance to both conventional and novel chemotherapy agents, and remains a major problem in cancer therapy. Resistance mechanisms are multifactorial and involve more strictly pharmacological factors, such as P-glycoprotein (P-gp) and biological factors such as inhibitor of apoptosis proteins (IAPs) and the nuclear factor-kappa B (NF-κB) pathway. Possible therapeutic strategies for the treatment of acute myeloid leukemia (AML) have increased in recent years; however, drug resistance remains a problem for most pa-tients. Phytol and heptacosane are the major compounds of Euphorbia intisy essential oil (EO) which were demonstrated to inhi…

phytolmultidrug resistanceP-gp inhibitorDrug DiscoveryP-glycoprotein; multidrug resistance; acute myeloid leukemia cell; P-gp inhibitors; phytol; heptacosaneheptacosaneSettore BIO/14 - FarmacologiaPharmaceutical ScienceMolecular MedicineP-glycoproteinSettore CHIM/08 - Chimica Farmaceuticaacute myeloid leukemia cell
researchProduct